HIV B-VAC project funded by ANRSART-TGSep 29, 20201 min readUpdated: May 10, 2021 ART-TG and VRI teams have received 3-year funding from ANRS to develop new HIV vaccines based on CRISPR genome editing of B cells.
Genomics and Genome Editing Quality Control Platform of ART-TG presented at the Genother Summit Meeting June 11, 25
Check our recent position paper on fresh CAR-T cell release; from the Bioproduction group of UNITC, the french CAR-T cell network.
Comments